Sun Pharma’s US antitrust payout won’t hurt finances, maintain ‘Buy’ rating: Nomura
NEW DELHI: Domestic drug major Sun Pharmaceutical’s $485 million settlement of antitrust litigations in the US will not cause any material financial stress or pose constraints to the firm’s plans for strategic investment, Nomura said.
“We…